FitLife Q2 revenue down 5% to $16.1M; completes $42.5M Irwin Naturals buy

FITLIFE BRANDS, INC.

2025-Q2 EPS reported $0.38 vs consensus $0.18 ▲ beat (+112.9%)

Net income $1.7M ($0.18 diluted EPS) vs $2.6M ($0.27) YoY; Adjusted EBITDA $3.3M, down 13%.
Gross margin fell to 42.8% from 44.8%; online revenue $10.4M (65% of total), down 7% YoY.
MRC segment revenue down 16%; Dr. Tobias brand declined 16% due to lower Amazon session counts.
Completed Irwin Naturals acquisition on Aug 8 for $42.5M; financed via $35.75M new term loan from First Citizens.
Irwin generated ~$60M revenue TTM at ~35% gross margin; FitLife expects ~$1.5M annual SG&A savings.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001437749-25-026674
form_type: 8-K
ticker: FTLF
cik: 0001374328
company_name: FITLIFE BRANDS, INC.
filed_at: 2025-08-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.837167+00:00
generated_at: 2026-05-17T12:58:10.540776+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001437749-25-026674
json_url: https://secwatch.observer/filing/0001437749-25-026674.json
markdown_url: https://secwatch.observer/filing/0001437749-25-026674.md
text_url: https://secwatch.observer/filing/0001437749-25-026674.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1374328/000143774925026674/0001437749-25-026674-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1374328/000143774925026674/ftlf20250814_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001437749-25-026674

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.